Rocky Mountain Spotted Fever (RMSF): Comprehensive Disease Research Report

1. Disease Information

Overview: Rocky Mountain spotted fever (RMSF) is a rare, acquired, life-threatening tick-borne infectious disease caused by Rickettsia rickettsii, an obligate intracellular, Gram-negative bacterium of the spotted fever group (SFG) rickettsiae. It is characterized by an acute onset of fever, malaise, and severe headache, followed in most patients by a characteristic centripetally-spreading petechial rash. It is the most severe and most frequently fatal rickettsial illness in the United States Orphanet: Rocky Mountain spotted fever.

Key Identifiers: - Orphanet ID: ORPHA:83311 - MONDO ID: MONDO:0019359 - ICD-10-CM: A77.0 - ICD-11: 1C31.0 - UMLS CUI: C0035793 - MeSH: D012373 (Rocky Mountain Spotted Fever) - No dedicated OMIM entry exists (RMSF is an acquired infectious disease, not a classically Mendelian OMIM phenotype)

Synonyms/alternative names: Tick typhus (Americas); "spotted fever" (historical, non-specific); São Paulo fever / febre maculosa brasileira (Brazilian form, caused by the same organism); New World spotted fever. Note: "spotted fever" as a general term (Wikidata Q9274700) also covers other SFG rickettsioses (Mediterranean spotted fever/R. conorii, etc.) and should not be conflated with RMSF specifically.

Data source type: Information is derived from aggregated disease-level resources (CDC national surveillance case counts, MMWR clinical guidelines, Orphanet/GARD rare disease summaries) and primary/case-series literature (individual patient case reports and cohort studies), rather than large-scale structured EHR datasets — consistent with a notifiable infectious disease under public health surveillance.

Sources: CDC – About RMSF, GARD, NORD, StatPearls

2. Etiology

Disease causal factor: RMSF is caused exclusively by infection with Rickettsia rickettsii (an obligate intracellular alphaproteobacterium, order Rickettsiales, family Rickettsiaceae), transmitted to humans via the bite of an infected hard tick. This is a purely infectious etiology — there is no known genetic disease-causing mutation; rather, host genetics modulates severity (see below), not occurrence.

Risk factors — environmental/exposure: - Tick exposure through outdoor occupational or recreational activity in endemic regions (camping, hiking, gardening, dog ownership) CDC Data & Statistics - Age >40 years is associated with highest reported incidence CDC - Male sex and possibly alcohol abuse are associated with increased risk of severe/fatal outcomes - Geographic residence in high-incidence states (North Carolina, Oklahoma, Arkansas, Tennessee, Missouri — >60% of U.S. cases) and in Arizona/northern Mexico border regions where Rhipicephalus sanguineus (brown dog tick)-associated epidemics produce unusually high incidence and case-fatality, particularly in children - Delay in initiating doxycycline (beyond day 5 of illness) is the single strongest modifiable risk factor for severe or fatal outcome

Genetic risk factor — G6PD deficiency: Glucose-6-phosphate dehydrogenase (G6PD) deficiency, an X-linked enzymopathy affecting ~10% of Black males in the U.S., is a documented genetic risk factor for fulminant RMSF (death by day 5 of illness). Walker et al. (PMID: 6687526) reported that "all three patients were male individuals of African descent with glucose-6-phosphate dehydrogenase (G6PD) deficiency," presenting with extensive thrombosis, fibrin thrombi at infection sites, absent/preterminal rash, severe pulmonary lesions, and shock-related organ damage including hepatic necrosis, despite minimal mononuclear inflammatory response on microscopy — an atypical, hyperacute pathological picture distinct from the classic vasculitic course.

Protective factors: No specific host genetic protective variant has been established. Prompt tick removal (reducing attachment time below the transmission threshold) and antimicrobial chemoprophylaxis are not recommended as primary prevention (post-exposure prophylactic antibiotics are explicitly discouraged by CDC because they may only delay, not prevent, illness).

Gene–environment interaction: The G6PD–RMSF interaction is the clearest documented gene-environment interaction: the underlying enzymatic deficiency does not cause disease alone but interacts with rickettsial infection (likely via unknown secondary effects of oxidative/hemolytic stress) to produce an accelerated, fulminant, thrombotic phenotype rather than the more typical subacute vasculitic course.

Suggested ontology terms: NCBITaxon:783 (Rickettsia rickettsii, per NCBI Taxonomy — verify directly), CHEBI/HGNC: G6PD (hgnc:4057).

3. Phenotypes

RMSF phenotypes are best organized as: (a) classic triad/early symptoms, (b) rash evolution, (c) gastrointestinal, (d) laboratory abnormalities, (e) neurological, (f) multi-organ/severe complications.

Classic triad

The classic triad of fever, headache, and rash is present in <5% of patients in the first 3 days of illness, rising to 60–70% by the second week CDC; emedicine. This low early sensitivity is the central diagnostic challenge in RMSF — treatment must not await the full triad.

• Fever — HP:0001945 (Fever); nearly universal, acute onset
• Severe headache (typically frontal) — HP:0002315 (Headache); majority of patients
• Malaise/fatigue — HP:0033834 or HP:0012378 (Fatigue)
• Myalgia — HP:0003326 (Myalgia)

Cutaneous

• Rash — HP:0000988 (Skin rash). Occurs in ~90% of cases eventually, but only in 1–4 days after symptom onset and in <50% during the first 3 days of illness. Classic evolution: begins on ankles/wrists as small, discrete, macular, blanching, rose-colored lesions; spreads centripetally to trunk and head over hours to days; becomes papular, then petechial/purpuric by day 2–3 of rash CDC signs & symptoms.
• Petechiae/purpura — HP:0000965 (Petechiae) / HP:0000978 (Bruising); a late, severity-associated sign
• Histopathology (skin biopsy): lymphohistiocytic capillaritis and venulitis with perivascular/interstitial infiltrate and erythrocyte extravasation; leukocytoclastic vasculitis with neutrophilic infiltrate and nuclear dust seen in 73% of biopsies; fibrin thrombi and capillary-wall necrosis in a minority; immunohistochemical staining for R. rickettsii is positive in affected endothelium in nearly all confirmed cases but only ~70% sensitive overall (Kao et al., J Cutan Pathol 1997; PMC workup ref).

Gastrointestinal

Gastrointestinal symptoms (anorexia, nausea, vomiting, abdominal pain) occur in up to 80% of patients; diarrhea in up to 45% — commonly leading to misdiagnosis as gastroenteritis, especially in children PMC8159303. - HP:0002018 (Nausea), HP:0002013 (Vomiting), HP:0002014 (Diarrhea), HP:0002027 (Abdominal pain), HP:0002039 (Anorexia)

Laboratory abnormalities

• Thrombocytopenia — HP:0001873; ~60% of patients; mechanistically attributed to intravascular platelet consumption from vasculitic endothelial injury
• Hyponatremia — HP:0002902; found in ~50–60% of cases, more common with CNS involvement, mechanistically linked to SIADH secondary to CNS vasculitis/inflammation
• Elevated liver enzymes — HP:0002910 (Elevated hepatic transaminase); >70% of patients with enzyme testing show at least one abnormality
• Elevated CSF protein/pleocytosis — CSF WBC >5/µL (pleocytosis) in 87.5% of meningoencephalitis cases; median CSF WBC 41 cells/µL; elevated protein (>50 mg/dL) in 87.5%; hypoglycorrhachia in 18.8% PMC5781900

Neurological (severe disease)

• Meningoencephalitis — HP:0002480 or HP:0002383 (Encephalitis); altered mental status, focal neurologic deficits, increased tone, reflex abnormalities
• Cerebral edema, cerebral infarction/stroke, cerebral vasospasm — HP:0002119 (Cerebral vasculitis-related); "starry sky" appearance on neuroimaging (perivascular/deep white-matter microinfarcts), especially in children
• Autopsy in fatal RMSF encephalitis shows gliosis, demyelination, and necrosis in affected brain regions

Multi-organ complications (severe/fatal disease)

Hepatic injury, renal failure, lobar pneumonia (non-cardiogenic pulmonary edema), meningoencephalitis, cardiac or respiratory failure, and disseminated intravascular coagulation (DIC) — typically emerging 8–15 days after onset in untreated/undertreated patients.

Phenotype characteristics

• Onset: Acute, 3–12 days post-tick-attachment (average ~7 days)
• Severity: Highly variable — from self-limited febrile illness to fulminant multi-organ failure within 5 days (G6PD-deficient patients)
• Progression: Rapidly progressive if untreated; can be halted/reversed with early doxycycline
• Quality of life impact: Long-term sequelae in survivors of severe (especially pediatric encephalitic) disease include behavioral disturbances and learning disabilities as the most commonly reported long-term problems MedLink Neurology; limb amputation has been reported after severe peripheral vasculitis/gangrene in fulminant cases.

4. Genetic/Molecular Information

RMSF is not a Mendelian/monogenic disease — there is no causal human gene. The relevant "genetic/molecular information" for this KB entry is twofold: (a) the human host modifier gene (G6PD) affecting severity, and (b) the pathogen's molecular virulence determinants.

Host modifier gene: - G6PD (glucose-6-phosphate dehydrogenase; HGNC:4057; X-linked) — deficiency is a documented severity modifier associated with fulminant, rapidly fatal RMSF (PMID: 6687526). This is not a "pathogenic variant causing RMSF" in the classic sense but a modifier/susceptibility relationship (relationship_type: MODIFIER or SUSCEPTIBILITY in dismech schema terms) — no specific G6PD allele/variant was singled out in the literature beyond "G6PD deficiency" broadly (common variants: G6PD A- in African-descent populations).

Pathogen (R. rickettsii) virulence factors — molecular mechanism: - rOmpA (outer membrane protein A, gene ompA) — surface autotransporter protein conserved throughout the spotted fever group; implicated in adhesion to host cells. Notably, targeted knockout of ompA in R. rickettsii did not diminish virulence in a mammalian (guinea pig) model, indicating redundancy among adhesins (Noriea et al., mBio 2015; PMC4453529). - rOmpB (outer membrane protein B, gene sca5) — conserved across both spotted-fever and typhus groups; implicated in both adhesion and invasion via interaction with the host receptor Ku70. - Sca1, Sca2, Sca4 ("gene D") — additional surface-cell-antigen (sca) family autotransporter proteins; Sca1 is the only sca gene present in all sequenced Rickettsia genomes. - Host receptor Ku70 — a subunit of DNA-dependent protein kinase (DNA-PKcs), identified as a mammalian receptor mediating rickettsial (initially characterized for R. conorii, homologous mechanism proposed for R. rickettsii) internalization via OmpB–Ku70 interaction, requiring cholesterol-rich membrane microdomain ubiquitination (mediated by c-Cbl ubiquitin ligase) and engaging clathrin/caveolin-2-dependent endocytosis (Martinez et al., Cell 2005, PMID: 16360032). - Additional endothelial receptors implicated with partial (~40% each) contribution when silenced individually: α2β1 integrin, FGFR1, Epac1 — indicating multiple redundant invasion pathways. - Post-invasion, R. rickettsii rapidly escapes the transient phagocytic vacuole (via phospholipase activity) to replicate freely in the host cytoplasm by binary fission, and spreads cell-to-cell by hijacking host actin polymerization machinery (actin-based motility), analogous to Listeria/Shigella.

Functional consequence: Loss-of-function of individual adhesins does not abrogate virulence (redundancy), but disruption of the invasion/intracytoplasmic-survival machinery broadly is essential to intracellular parasitism and endothelial tropism.

Epigenetics / chromosomal abnormalities: Not applicable — RMSF has no described epigenetic disease mechanism or chromosomal abnormality; it is an acute bacterial infection.

Suggested ontology terms: hgnc:4057 (G6PD); GO:0044409 (entry into host), GO:0075512 (clathrin-dependent endocytosis of virus by host cell — analogous GO term set exists for bacteria under GO:0035821 modulation of process of another organism); CHEBI not directly applicable to pathogen proteins.

5. Environmental Information

Environmental/vector factors: - Primary tick vectors (United States): - Dermacentor variabilis (American dog tick) — most frequently associated with transmission; found in eastern, central, and Pacific coastal U.S. - Dermacentor andersoni (Rocky Mountain wood tick) — western U.S. vector - Rhipicephalus sanguineus (brown dog tick) — increasingly important vector in Arizona and along the U.S.–Mexico border, associated with unusually high incidence and case-fatality (especially pediatric) in that region - Free-roaming dog populations and peridomestic tick infestations are key amplifying factors in the brown-dog-tick-driven Arizona/Sonora epidemic - Tick attachment duration is a critical transmission determinant: unfed nymphs/adults require >10 hours of attachment for transmission, whereas ticks that have already partially fed can transmit in as little as ~10 minutes (reflecting rickettsial "reactivation"/increased virulence after a blood meal) — earlier literature commonly cites a 4–6 hour minimum attachment threshold. - Seasonality: Peak May–August (tick questing season), though cases occur year-round, especially in warmer southern latitudes.

Lifestyle factors: Occupational/recreational outdoor activity (agriculture, forestry, hiking, camping), dog ownership (dogs both serve as sentinel hosts and can carry ticks into the home/peridomestic environment).

Infectious agent: Rickettsia rickettsii — obligate intracellular, aerobic, Gram-negative coccobacillus; taxonomically placed in order Rickettsiales, family Rickettsiaceae, genus Rickettsia, spotted fever group. (NCBI Taxonomy ID for R. rickettsii should be independently confirmed at ncbi.nlm.nih.gov/taxonomy — not definitively retrieved in this search pass.)

Sources: CDC clinical overview, MMWR RR6502a1

6. Mechanism / Pathophysiology

Causal chain overview: Tick bite → dermal/subcutaneous rickettsial inoculation → hematogenous/lymphatic dissemination → endothelial cell invasion (via OmpA/OmpB-mediated adhesion, Ku70/integrin/FGFR1/Epac1-mediated receptor engagement, and cholesterol-microdomain-dependent, ubiquitin/clathrin/caveolin-2-facilitated endocytosis) → rapid escape from the phagosome into free cytoplasmic residence → intracellular replication and cell-to-cell spread via actin-based motility → direct and immune-mediated endothelial injury → disseminated small-vessel vasculitis → increased microvascular permeability, coagulation activation, and multi-organ dysfunction.

Endothelial injury and vascular permeability (central pathophysiologic event): "Fatal rickettsioses are fundamentally a vasculitis" — R. rickettsii directly infects microvascular endothelial cells throughout the body, and the dominant pathophysiological effect is markedly increased vascular permeability, producing vasogenic cerebral edema and non-cardiogenic pulmonary edema (Walker/Olano/UTMB review; ScienceDirect overview). A key molecular mechanism: rickettsial infection induces phosphorylation of VE-cadherin, directly attenuating homophilic adherens-junction protein–protein interactions, causing endothelial paracellular barrier dysfunction and microvascular hyperpermeability (Woods & Olano, PMC3373609). Rickettsial infection also disrupts and reduces the tight-junction protein zonula occludens-1 (ZO-1), associated with inflammasome activation (PMC11784141). Oxidative injury via generation of oxygen free radicals by infected endothelial cells further compounds membrane injury (PMID 9720025-class studies).

Coagulopathy/thrombocytopenia: Endothelial injury exposes subendothelial collagen/tissue factor, triggering platelet adhesion/activation and consumption (intravascular platelet destruction), together with mild activation of the coagulation cascade (increased fibrinogen, mildly prolonged aPTT) — producing the characteristic thrombocytopenia and, in severe/fulminant cases, disseminated intravascular coagulation with fibrin thrombi (PMID: 2105679, canine model). Retinal vasculitic foci correlate temporally (24–48h post-fever onset) with areas of altered vascular permeability, providing a directly visualizable model of the systemic process.

Immune response: Clearance of rickettsiae is critically dependent on cytotoxic CD8+ T lymphocytes and interferon-gamma (IFN-γ) — in murine models, MHC class I-knockout mice were >50,000-fold more susceptible to lethal rickettsial infection than wild-type, indicating CTL activity is more critical than IFN-γ effects alone for recovery (Walker, Olano, Feng; PMID: 11179362). CD4+ T cells also contribute via macrophage activation (iNOS/NO-mediated bactericidal activity), and macrophages/infiltrating T-lymphocytes produce cytokines that both control infection and, paradoxically, worsen vascular permeability/injury as part of the host inflammatory response to endothelial infection (PMC3691998, "Host Defenses to R. rickettsii Infection Contribute to Increased Microvascular Permeability").

Cellular processes and cell types involved: - Endothelial cells (primary target; CL:0000115 endothelial cell) — direct infection, junctional disruption, apoptosis-resistance subversion to prolong the intracellular replicative niche - Platelets (CL:0000233) — consumption/aggregation at sites of endothelial injury - Macrophages/monocytes (CL:0000235) and CD8+/CD4+ T lymphocytes (CL:0000625, CL:0000624) — immune clearance and inflammatory amplification - Perivascular dermal and CNS vasculature — site of clinically visible vasculitis (skin) and of encephalitis-associated microinfarction (brain)

Tissue damage mechanisms: Vasculitis-driven ischemia/microinfarction, vasogenic edema, oxidative stress, and (in fulminant G6PD-deficient cases) thrombotic microangiopathy with fibrin thrombi and organ necrosis (notably hepatic necrosis) in the near-absence of the typical mononuclear inflammatory infiltrate — suggesting a distinct, more hyperacute/thrombotic pathological subtype in this genetically susceptible group.

Suggested GO terms: - GO:0007566 / more precisely bacterial entry processes — GO:0044409 (entry into host), GO:0035821 (modulation of process of another organism) - GO:0016477 (cell migration) / actin-based motility analogous to GO:0030044 (in intracellular pathogen movement literature, often annotated under host actin cytoskeleton reorganization, GO:0030036) - GO:0034332 (adherens junction organization) — for VE-cadherin disruption - GO:0002532 (production of molecular mediator involved in inflammatory response), GO:0050818 (regulation of coagulation) - GO:0001525 (angiogenesis) not directly relevant; better: GO:0061028 (establishment of endothelial barrier), GO:0061028 disruption

Suggested CL terms: CL:0000115 (endothelial cell), CL:0000235 (macrophage), CL:0000624 (CD4-positive T cell), CL:0000625 (CD8-positive T cell), CL:0000233 (platelet)

7. Anatomical Structures Affected

Organ level: - Primary: Skin/cutaneous microvasculature (rash), systemic small blood vessels (arterioles, capillaries, venules) throughout the body — RMSF is fundamentally a systemic small-vessel vasculitis, not confined to one organ. - Secondary/complication organs: Brain (meningoencephalitis, cerebral edema, infarction — UBERON:0000955), lungs (non-cardiogenic pulmonary edema/ARDS — UBERON:0002048), liver (hepatocellular injury/necrosis — UBERON:0002107), kidneys (acute kidney injury — UBERON:0002113), heart (myocarditis/cardiac dysfunction — UBERON:0000948), gastrointestinal tract (UBERON:0001555, prominent early symptoms), retina (vasculitis visible on fundoscopy — UBERON:0000966), adrenal glands (case reports of adrenal hemorrhage/adrenalectomy) - Body systems involved: Integumentary, cardiovascular, nervous, respiratory, digestive, renal, hematologic/coagulation

Tissue/cell level: - Vascular endothelium (UBERON:0002316 blood vessel endothelium) is the principal cellular target — infection is fundamentally endotheliotropic - Dermal capillaries/venules (histopathology: lymphohistiocytic capillaritis/venulitis) - CNS white matter (perivascular microinfarcts, demyelination in fatal encephalitis)

Subcellular level: - Host cytoplasm (site of rickettsial replication after phagosomal escape) — GO:0005737 - Cholesterol-enriched plasma membrane microdomains (site of Ku70-mediated invasion) — GO:0005886 / lipid raft GO:0045121 - Adherens junctions (VE-cadherin) — GO:0005912; tight junctions (ZO-1) — GO:0005923

Localization: Systemic/disseminated — not focal or lateralized; skin rash is bilateral, acral-onset with centripetal spread.

8. Temporal Development

• Onset: Acute; incubation period 3–12 days post-tick-attachment, average ~7 days (shorter incubation correlates with higher inoculum/exposure magnitude)
• Onset pattern: Abrupt febrile illness
• Progression: Classic disease course over the first 1–2 weeks: nonspecific febrile prodrome (days 1–3, often without rash) → rash onset (days 3–5) → petechial/purpuric evolution (days 5–7) → in untreated or delayed-treatment cases, multi-organ complications (days 8–15) → death (median around day 8–9 in fatal untreated cases; as early as day 5 in "fulminant" G6PD-deficient cases)
• Disease course pattern: Monophasic acute illness (not relapsing-remitting); resolves fully with prompt treatment; can progress to fulminant multisystem failure without treatment
• Duration: Self-limited with appropriate antibiotic therapy (clinical improvement typically within 24–72 hours of starting doxycycline); potentially fatal (days) without treatment
• Remission: Treatment-induced; no spontaneous remission mechanism reported once vasculitic phase is established — untreated case-fatality is 20–30%
• Critical period for intervention: Treatment initiated within the first 5 days of symptom onset is strongly associated with reduced morbidity/mortality — this is the single most important "critical window" in RMSF management

9. Inheritance and Population

RMSF is an acquired infectious disease with no Mendelian inheritance pattern. Population/epidemiological data:

Epidemiology: - 2023 U.S. surveillance: 1,205 cases of spotted fever rickettsioses (including RMSF) reported to CDC CDC Data & Statistics - Geographic concentration: >60% of cases in North Carolina, Oklahoma, Arkansas, Tennessee, and Missouri - Distinct high-incidence/high-case-fatality foci: Arizona and northern Mexico border regions (brown-dog-tick-transmitted, disproportionately affecting children) - Seasonality: year-round with a strong May–August peak

"Inheritance"-analog (host modifier): G6PD deficiency is X-linked recessive (as a modifier, not disease-causing) — hemizygous males (and rarely homozygous females) are at higher risk for fulminant disease.

Population demographics: - Age: Highest reported incidence in adults >40 years old, but case-fatality is disproportionately high in young children (especially in the Arizona/brown-dog-tick epidemic) - Sex: Male sex is associated with increased risk of severe/fatal complications - Ethnicity/genetic background: African-descent males with G6PD deficiency are at particular risk for fulminant, rapidly fatal disease - Mortality: Case-fatality rate <0.5% with modern treatment nationally (varies significantly by region — much higher, historically 20-30%, in the pre-antibiotic/untreated era, and elevated in the Arizona tribal-community outbreaks)

Sources: CDC facts & stats, MMWR RR6502a1, PMC12928218 — pediatric mortality predictors, Sonora Mexico

10. Diagnostics

Clinical/laboratory tests: - PCR — detects R. rickettsii DNA from blood, plasma, or skin biopsy tissue; limited sensitivity early because the organism is endotheliotropic and does not circulate in large numbers in blood until disease is advanced; a negative PCR does not rule out RMSF and should never delay treatment CDC diagnosis/testing - Serology (IFA) — the standard serologic test is the indirect immunofluorescence assay (IFA) for IgG against R. rickettsii antigen; requires paired acute and convalescent sera 2–10 weeks apart demonstrating a ≥4-fold rise in titer; antibody titers are frequently negative in the first week of illness (a major diagnostic limitation — serology confirms retrospectively, it does not guide acute treatment decisions) - Skin biopsy with immunohistochemistry (IHC)/direct immunofluorescence — detects rickettsial antigen in endothelial cells of biopsied rash lesions; most sensitive in early disease before antibiotics are started, but available only at specialized reference laboratories (CDC); ~70% sensitivity even under optimal conditions - Laboratory abnormalities supportive of diagnosis (non-specific but pattern-suggestive): thrombocytopenia, hyponatremia, elevated hepatic transaminases, elevated CSF protein/pleocytosis in CNS disease - Imaging: Brain MRI in encephalitic cases may show the "starry sky" pattern of scattered perivascular/deep white-matter microinfarcts, meningeal enhancement, or cerebral edema

Genetic testing: Not applicable to the infection itself; G6PD enzyme activity testing (or genetic testing for G6PD variants) may be clinically relevant in patients (especially Black males) presenting with unusually fulminant/hyperacute RMSF, to explain severity and anticipate hemolysis risk, though this is not a diagnostic test for RMSF itself.

Clinical criteria: RMSF is a clinical diagnosis requiring empiric treatment — CDC/AAP explicitly recommend starting doxycycline based on clinical suspicion (fever + history of tick exposure in an endemic area/season ± rash) without waiting for laboratory confirmation, given the narrow therapeutic window. Case is classified as "probable" or "confirmed" retrospectively per CDC/CSTE surveillance case definitions (using the 4-fold IFA titer rise, PCR, IHC, or culture isolation as confirmatory criteria).

Differential diagnosis: Other spotted fever group rickettsioses, ehrlichiosis, anaplasmosis, meningococcemia, measles, enteroviral illness, viral exanthems, gastroenteritis (particularly in children, given the high frequency of GI symptoms), Kawasaki disease, drug reaction/Stevens-Johnson-type eruptions, leptospirosis, and dengue (in travel-relevant settings).

Screening: No population screening program exists; case-finding relies on clinical suspicion in tick-exposed patients during peak season in endemic regions.

Suggested NCIT terms: NCIT:C15473 (Polymerase Chain Reaction), NCIT:C15188 (Serology), skin biopsy → NCIT:C15230 (Biopsy Procedure)/immunohistochemistry NCIT:C16336.

11. Outcome/Prognosis

Mortality: - Untreated/inadequately treated: case-fatality historically 20–30% - Treated (modern era): case-fatality <1% overall; U.S. national surveillance estimates <0.5%, though this varies substantially by region, with much higher rates in specific high-burden pediatric/Indigenous-community outbreaks in Arizona/Sonora - Risk factors for fatal outcome: advanced age, male sex, delayed diagnosis/treatment (particularly beyond day 5), G6PD deficiency (fulminant subtype), possibly alcohol use disorder

Morbidity/complications: Hepatic injury, renal failure, pneumonia/ARDS, meningoencephalitis, cardiac/respiratory failure, DIC, digit/limb gangrene requiring amputation in severe vasculitic/thrombotic cases, and — in survivors of severe pediatric encephalitis — long-term behavioral disturbances and learning disabilities as the most commonly reported sequelae.

Recovery potential: Excellent with treatment initiated early (within 5 days) — most patients recover fully without sequelae. Recovery potential drops sharply once multi-organ vasculitic complications (renal failure, ARDS, DIC, encephalitis) have developed.

Prognostic factors: Time to treatment initiation (dominant factor), presence/severity of neurologic involvement, G6PD status, age extremes, and degree of thrombocytopenia/coagulopathy at presentation.

12. Treatment

Pharmacotherapy (first-line): - Doxycycline is the first-line treatment for all patients regardless of age, including children <8 years old and pregnant women — this is an explicit, evidence-based departure from the older tetracycline-class contraindication in young children. Multiple studies have shown that short courses (5–10 days) of doxycycline used for RMSF, even across up to five treatment courses before age 8, do not cause permanent tooth staining or enamel hypoplasia CDC — doxycycline & tooth staining research. Treatment should begin empirically based on clinical suspicion, ideally within the first 5 days of symptom onset, without waiting for laboratory confirmation. - NCIT term: NCIT:C820 (Doxycycline) under NCIT:C15986 (Pharmacotherapy) - Chloramphenicol — the only alternative agent with historical use, reserved for patients with life-threatening doxycycline allergy or in mild disease in pregnant patients; associated with increased mortality risk compared to doxycycline and carries risks of aplastic anemia and gray baby syndrome; oral formulation is not available in the U.S. - Explicit safety point: "Use of antibiotics other than doxycycline increases the risk of patient death" emedicine treatment

Pregnancy: Doxycycline is recommended as first-line even in pregnancy given the severity of untreated RMSF; available data suggest low risk of substantial teratogenicity at RMSF treatment dosing/duration.

Supportive care: Fluid/electrolyte management (for hyponatremia), transfusion support for severe thrombocytopenia/coagulopathy, ICU-level supportive care (mechanical ventilation, vasopressors, renal replacement therapy) for fulminant multi-organ disease. NCIT:C15747 (Supportive Care).

No vaccine currently exists for RMSF; prevention is entirely non-pharmacologic (see Section 13).

No targeted/gene/cell/immunotherapies are applicable — RMSF treatment is standard antimicrobial pharmacotherapy plus supportive care; there are no RMSF-specific clinical trials of novel therapeutics identified in this search (research is ongoing into recombinant rickettsial antigen vaccines, still preclinical/veterinary stage — see canine whole-cell antigen vaccine studies).

13. Prevention

Primary prevention (no vaccine available for humans): - Repellents: EPA-registered repellents containing DEET, picaridin, IR3535, oil of lemon eucalyptus (OLE), PMD, or 2-undecanone applied to skin - Acaricide/permethrin: 0.5% permethrin applied to clothing/gear (not skin) — effective at killing/repelling ticks - Protective clothing: long sleeves/pants, tucking pants into socks - Behavioral: avoiding tall grass, leaf litter, brushy trails, especially May–August in endemic regions - Post-exposure: full-body tick checks, checking pets/gear, showering promptly after outdoor exposure to remove unattached ticks (reducing the critical attachment-time window needed for transmission)

Secondary prevention: Prompt tick removal reduces transmission risk given the attachment-time dependence of transmission (though CDC does not recommend prophylactic antibiotics after a tick bite, as data do not support this practice preventing RMSF).

Public health/vector control: Environmental/peridomestic acaricide treatment and stray-dog population control have been used as public health interventions in the Arizona/Sonora brown-dog-tick epidemic (modeling studies on Rhipicephalus sanguineus control, PMC8951036).

Veterinary/One Health prevention: Tick control on dogs (topical/oral acaricides) reduces both canine disease and human exposure risk from peridomestic ticks, especially relevant to the brown dog tick transmission cycle.

Vaccine status: No licensed human vaccine; experimental whole-cell inactivated R. rickettsii vaccines have shown protective efficacy in the canine model (PMC12707144, PMC6346123) but are not available for human use.

14. Other Species / Natural Disease

Taxonomy: R. rickettsii naturally infects a broad range of vertebrate hosts and tick vectors across the Americas (North, Central, and South America — the same organism causing "febre maculosa brasileira" in Brazil).

Natural disease in companion animals — dogs (primary veterinary relevance): Dogs are naturally, highly susceptible to R. rickettsii infection and serve as important sentinel hosts due to high tick exposure. Clinical signs in dogs closely parallel human disease: high fever (up to 105°F/40.6°C), anorexia, lymphadenopathy, polyarthropathy, cough/dyspnea, abdominal pain, vomiting, diarrhea, and facial/limb edema Merck Veterinary Manual. A detailed natural-history study of experimentally tick-bite-infected dogs characterized clinical, hematological, molecular, and serological dynamics from exposure through convalescence and relapse (PMC4277292).

Comparative biology: The canine disease recapitulates the vasculitic/coagulopathic pathophysiology of human RMSF closely enough that experimental canine infection (via tick bite, the natural route) has been used as a translational model for vaccine development (whole-cell antigen vaccines protective in dogs, PMC6346123, PMC12707144) and for characterizing vascular permeability/coagulation pathophysiology (PMID: 2105679, foundational canine coagulation study).

Zoonotic/transmission considerations: RMSF is a zoonosis maintained in nature by tick–small-mammal (and, regionally, tick–dog) cycles; it is not communicable person-to-person (with rare, unconfirmed exceptions for blood transfusion; no documented transplant transmission). Dogs act as both amplifying/sentinel hosts and as tick-carriers into human peridomestic environments, making canine surveillance and tick control a key "One Health" intervention point, especially in the brown-dog-tick-driven Arizona epidemic.

15. Model Organisms

Mouse models: - C3H/HeN mice — described as providing "the best model to date for examining rickettsial disease with endothelial infection and injury." While much of the detailed published characterization uses the closely related R. conorii (Mediterranean spotted fever agent) in C3H/HeN mice — establishing disseminated endothelial infection by day 1, progressive rickettsemia, and death from vascular-injury-based meningoencephalitis and interstitial pneumonia by day 5–6 — this endothelial-target model system has also been used directly for R. rickettsii vaccine/pathogenesis studies. It recapitulates the core human pathophysiology: endotheliotropism, vasculitis-driven CNS and pulmonary injury. - MHC class I-knockout mice (C57BL/6 background) — used to demonstrate the essential role of CD8+ cytotoxic T lymphocytes in rickettsial clearance (>50,000-fold increased susceptibility to lethal outcome vs. wild-type) — a genetic immunodeficiency model rather than a disease-replicating model per se, but critical for defining protective immune mechanisms (PMID: 11179362). - Guinea pig model — used in virulence studies of R. rickettsii mutants (e.g., ompA knockout, which did not attenuate virulence), providing a classic rickettsiosis animal model with fever and scrotal/testicular necrosis as a virulence readout (Noriea et al., mBio 2015).

Canine model (natural/experimental): As above — the dog is both a natural disease host and a valuable experimental model (tick-bite-route infection) because it reproduces the vasculitic, coagulopathic, and clinical syndrome of human RMSF with high fidelity, and has been used for both pathophysiology studies (vascular permeability/coagulation, PMID 2105679) and vaccine efficacy testing.

Model limitations: Mouse models (especially with R. conorii rather than R. rickettsii itself) may not fully capture R. rickettsii-specific virulence factor biology (e.g., the ompA knockout virulence result may not generalize across species); the canine model, while pathophysiologically faithful, does not model human-specific risk factors such as G6PD deficiency-associated fulminant disease. No model has been reported that specifically recapitulates the G6PD-deficiency-associated fulminant/thrombotic human phenotype.

Applications: Endothelial infection/injury mechanisms, vascular permeability biology (VE-cadherin phosphorylation, ZO-1 disruption), immune clearance mechanisms (CD8+ T cell/IFN-γ dependence), and vaccine antigen efficacy testing (recombinant/whole-cell antigen protection studies in both mice and dogs).

Ontology Term Summary Table

(Ontology mappings above are research suggestions and should be independently verified with OAK/runoak against the local sqlite adapters before use in a KB entry, per dismech curation SOP.)

Key Primary Sources Cited

• Walker DH et al. Fulminant Rocky Mountain spotted fever and G6PD deficiency. Arch Pathol Lab Med 1983;107(3):121-5. PMID: 6687526
• Martinez JJ et al. Ku70, a component of DNA-dependent protein kinase, is a mammalian receptor for Rickettsia conorii. Cell 2005. PMID: 16360032
• Feng HM, Whitworth T, Popov V, Walker DH. Critical role of cytotoxic T lymphocytes in immune clearance of rickettsial infection. Infect Immun 2001;69:1841-6. PMID: 11179362
• Noriea NF et al. Targeted knockout of the Rickettsia rickettsii OmpA surface antigen does not diminish virulence. mBio 2015. PMC4453529
• Woods ME, Olano JP. Host defenses to Rickettsia rickettsii infection contribute to increased microvascular permeability. PMC3691998
• Canine coagulation/vascular permeability study. PMID: 2105679
• CDC. Diagnosis and Management of Tickborne Rickettsial Diseases, MMWR RR6502a1: link
• CDC. Signs & Symptoms, Diagnosis/Testing, Clinical Care, Facts & Stats pages: cdc.gov/rocky-mountain-spotted-fever
• Orphanet: ORPHA:83311; GARD: rarediseases.info.nih.gov

Note on gaps: No dedicated OMIM phenotype entry exists (expected, as RMSF is acquired/infectious). Precise NCBI Taxonomy IDs for Dermacentor variabilis/andersoni/Rhipicephalus sanguineus and confirmed R. rickettsii NCBITaxon ID were not definitively retrieved in this pass and should be looked up directly at ncbi.nlm.nih.gov/taxonomy before KB entry. No published RMSF-specific GWAS or additional host susceptibility loci beyond G6PD were identified.